Tesla now stands at a pivotal crossroads:  • In the U.S., the “Big Beautiful Bill” has eliminated the $7,500 federal EV tax credit and...

Between 2025–2028, Merck’s Keytruda (pembrolizumab) and BMS’s Opdivo (nivolumab)—together generating approximately $38B+ in annual...

As vacancy rates climb and valuations reset, the U.S. office sector is facing a historic transformation. But hidden in this disruption is...